Portal:CPTAC/Hallmark/Therapeutics
From WikiPathways
(Difference between revisions)
(added new NRF2 pathway) |
(adding WP4301) |
||
| Line 7: | Line 7: | ||
*[[Pathway:WP3]] Phytochemical activity on NRF2 transcriptional activation | *[[Pathway:WP3]] Phytochemical activity on NRF2 transcriptional activation | ||
*[[Pathway:WP4357]] NRF2-ARE regulation | *[[Pathway:WP4357]] NRF2-ARE regulation | ||
| + | *[[Pathway:WP4301]] Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells | ||
Revision as of 01:41, 5 December 2018
- Pathway:WP3672 LncRNA-mediated mechanisms of therapeutic resistance
- Pathway:WP3640 Imatinib and Chronic Myeloid Leukemia
- Pathway:WP3614 Photodynamic therapy-induced HIF-1 survival signaling
- Pathway:WP3617 Photodynamic therapy-induced NF-kB survival signaling
- Pathway:WP3879 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression
- Pathway:WP1601 Fluoropyrimidine Activity
- Pathway:WP3 Phytochemical activity on NRF2 transcriptional activation
- Pathway:WP4357 NRF2-ARE regulation
- Pathway:WP4301 Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells
